Evaluation of Antibacterial Activity of Piper betel Leaves and Nigella sativa Seeds against Multidrug Resistant Food and Water Borne Pathogenic Bacteria: An in vitro Study Model

2018 ◽  
Vol 22 (4) ◽  
pp. 1-11 ◽  
Author(s):  
Md Rahman ◽  
Md Wadud ◽  
Tarequl Islam ◽  
Md Hussain ◽  
Esfat Bristy ◽  
...  
Omni-Akuatika ◽  
2019 ◽  
Vol 15 (1) ◽  
pp. 30
Author(s):  
Ikfa Permatasari ◽  
Fiddy Semba Prasetiya ◽  
Sulastri Arsad ◽  
Mochamad Untung Kurnia Agung ◽  
Jean-Luc Mouget

Haslea ostrearia has known as the only diatom which synthesizes a water-soluble blue pigment, marennine. It has some biological activities such as allelopathy, antioxidant, antibacterial, antiviral, and growth inhibitor. Marennine is available in two forms, intracellular which located in the apical of the cell and extracellular which released into the culture medium. This research aimed to test the bioactivity of Haslea ostrearia supernatant adapted in Indonesia as an antibacterial against pathogenic bacteria relevant to marine culture using in-vitro study. This research was using an explorative method, data analysed statistically and descriptive-comparatively observed. Observation parameters were the inhibitory zone of antibacterial activity, absorbance value of MIC test, and bacterial growth qualitatively from MBC test. Marennine concentration in the supernatant of Haslea ostrearia adapted in Indonesia is about 3.74 mg. L-1. The highest concentration supernatant of Haslea ostrearia that shown antibacterial activity is 3.5 mg. L-1 with inhibitory zone diameter is about 6.87 mm for Staphylococcus aureus and 7.14 mm for Vibrio harveyi, correspondingly. The minimum concentration that inhibits the growth of Staphylococcus aureus is 0.03 mg. L-1, while for Vibrio harveyi is 0.06 mg. L-1. Antibacterial activity of supernatant Haslea ostrearia originally adapted in Indonesia classified into bacteriostatic


2019 ◽  
Vol 7 (4) ◽  
pp. 91-96
Author(s):  
Isra'a Al-sobhi ◽  
◽  
Rawan Al-Ghabban ◽  
Soad Shaker Ali ◽  
Jehan Al-Amri ◽  
...  

Author(s):  
Fouad Hussain Al-Bayaty ◽  
Mahmood Ameen Abdulla ◽  
Mohamed Ibrahim Abu Hassan ◽  
Siti Noraini Binti Roslan ◽  
Saba Fouad Hussain ◽  
...  

Author(s):  
Luigi de Nardo ◽  
Ilaria Alfieri ◽  
Andrea Lorenzi ◽  
Enrica Saino ◽  
Livia Visai ◽  
...  

2016 ◽  
Vol 30 (6) ◽  
pp. 1192-1198 ◽  
Author(s):  
Esra Yesiloz Gokcen ◽  
Firdevs Tulga Oz ◽  
Berrin Ozcelik ◽  
Ayse Isıl Orhan ◽  
Betul Memis Ozgul

2020 ◽  
Vol 23 (4) ◽  
pp. 8p ◽  
Author(s):  
Prasanna T. Dahake ◽  
Sudhindra M Baliga

Background: Removal of all the pathogenic bacteria from the root canal system is of prime importance for the success of endodontic therapy. Objective: The study aimed to determine the antimicrobial efficacy of three antibiotics and their new combination against selected endodontic pathogens. Methods: In this in-vitro study, we used bacterial strains associated with the refractory endodontic condition and determined MIC and MBC of Clindamycin (C), Metronidazole (M), Doxycycline (D) as well as their combination CMD. We cultured Candida Albicans, Pseudomonas Aeruginosa, Escherichia Coli, Enterococcus Faecalis, Streptococcus Mutans, Bacillus Subtilis subsp. spizizenii, Actinomyces Actinomycetemcomitans on selective culture media. We analyzed the data using paired 't' test, one-way ANOVA, and Tuckey's HSD post hoc test. Results: Clindamycin inhibited the growth of C. Albicans (90%) and S. Mutans (90%) significantly and P. Aeruginosa, E. Coli, E. Faecalis, B. Subtilis, and A. Actinomycetemcomitans were resistant to it. Metronidazole did not inhibit any of the bacteria. Doxycycline inhibited C. Albicans (90%), P. Aeruginosa (90%), and S. Mutans (90%) significantly while E. Coli, E. Faecalis, B. Subtilis, and A. Actinomycetemcomitans were resistant to it. The combination of CMD inhibited all the microbes significantly. However, at bactericidal concentrations of CMD, E. Faecalis (p = 0.024), B. Subtilis (p = 0.021) and A. Actinomycetemcomitans (p = 0.041) were eliminated significantly, while C. Albicans (p = 0.164), P. Aeruginosa (p = 0.489), E. Coli (p = 0.106) and S. Mutans (p = 0.121) showed resistance. Conclusion: Combination CMD can be used against resistant endodontic pathogens to achieve predictable endodontic results.KEYWORDSAntimicrobial agents; Clindamycin; Doxycycline; Metronidazole; Root canal therapy.    


Sign in / Sign up

Export Citation Format

Share Document